Context Therapeutics Inc.

Overview

Compare with another stock.

• TickerCNTX on Nasdaq²
• IndustryPharmaceutical Preparations²
• HeadquartersPhiladelphia, United States²
• Incorporated inDE³
• Business address2001 Market Street, Suite 3915 Unit #15, Philadelphia, Pa 19103³
• Filer category, Emerging growth company³
• Legal formCorporation²
• LEI549300U5ISIWCBXD6W77²
• StatusActive²
• LEI statusLapsed (not renewed)²
• Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States²
• Registered withDivision of Corporations, Department of State, 5700752²

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (“CLDN6”) x CD3 TCE, CT-95, a Mesothelin (“MSLN”) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (“Nectin-4”) x CD3 TCE.⁴ From its latest annual report

Corporate structure

Context Therapeutics Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Context Therapeutics Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

Our corporate headquarters are located at 2001 Market Street, Suite 3915, Unit #15, Philadelphia, PA 19103, where we occupy approximately 6,200 square feet of office space pursuant to a lease most recently amended in January 2026 that expires on November 30, 2027. This amended lease included additional office space and allows us to renew the lease at our option for one additional successive one-year period. We believe our facility is adequate to meet our current needs, although we may seek to negotiate new leases or evaluate additional or alternate space for our operations. If needed, we believe appropriate alternative space will be readily available on commercially reasonable terms.

Item 2 of the 10-K filed Mar 23, 2026.⁴

Leadership

Who has led Context Therapeutics Inc., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerMartin A. Lehr Oct 19, 2021 to now¹²
• Chief financial officerJennifer Lynn Minai-Azary Nov 1, 2021 to now¹³

Named in SEC Form D filings

People the company listed in its private-offering notices.

• DirectorRichard Jay Berman named May 16, 2024²⁶

Former names

• Context Therapeutics LLCMar 19, 2021 to May 3, 2021³

Timeline

1. Aug 5, 20268-K Regulation FD disclosure²⁷
2. Jul 31, 20268-K Listing notice or transfer²⁸
3. Jun 26, 20268-K Bylaws or fiscal year changed; Shareholder vote²⁹
4. Jun 15, 20268-K Regulation FD disclosure; Other events³⁰
5. May 18, 20268-K Entered a material agreement; Regulation FD disclosure³¹
6. May 1, 20268-K Other events³²
7. Apr 2, 20268-K Regulation FD disclosure; Other events³³
8. Mar 23, 20268-K Regulation FD disclosure; Other events³⁴
9. Mar 13, 20268-K Bylaws or fiscal year changed; Other events³⁵
10. Feb 27, 20268-K Other events³⁶
11. Jan 8, 20268-K Regulation FD disclosure³⁷
12. Nov 5, 20258-K Regulation FD disclosure; Other events³⁸
13. Oct 19, 2021New chief executive Martin A. Lehr becomes CEO¹²

Calendar

Coming up

1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.10) a share, on Nov 5, 2025.³⁹

When it reported results

1. Mar 22, 2023Reported quarterly or annual results⁴⁰
2. Mar 23, 2022Reported quarterly or annual results⁴¹
3. Dec 2, 2021Reported quarterly or annual results⁴²

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

273 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 88 insider forms, 45 large holders, 1 private raises, 66 other. The latest 20:

1. Aug 14, 2026SCHEDULE 13G/A EDGAR
2. Aug 12, 2026SCHEDULE 13G/A EDGAR
3. Aug 5, 20268-K EDGAR
4. Aug 5, 202610-Q EDGAR
5. Jul 31, 20268-K EDGAR
6. Jul 31, 2026SCHEDULE 13G/A EDGAR
7. Jul 27, 2026SCHEDULE 13G EDGAR
8. Jun 26, 20264 EDGAR
9. Jun 26, 20264 EDGAR
10. Jun 26, 20264 EDGAR
11. Jun 26, 20264 EDGAR
12. Jun 26, 20264 EDGAR
13. Jun 26, 20264 EDGAR
14. Jun 26, 20268-K EDGAR
15. Jun 15, 20268-K EDGAR
16. May 18, 20268-K EDGAR
17. May 15, 2026SCHEDULE 13G/A EDGAR
18. May 14, 2026SCHEDULE 13G EDGAR
19. May 14, 2026SCHEDULE 13G/A EDGAR
20. May 12, 2026SCHEDULE 13G/A EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

19 open-market trades by officers, directors and large owners since October 2021: 19 buys and 0 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• MPM BioImpact LLCSCHEDULE 13G/A, 3 filings Jan 8, 2025 to Aug 14, 2026⁴³
• Blue Owl CapitalSCHEDULE 13G/A, 4 filings Nov 14, 2024 to Aug 12, 2026⁴⁴
• Octagon Capital Advisors LPSCHEDULE 13G/A, 2 filings May 14, 2026 to Jul 31, 2026⁴⁵
• BlackRockSCHEDULE 13G, 1 filing Jul 27, 2026⁴⁶
• GREAT POINT PARTNERS LLCSCHEDULE 13G/A, 8 filings Jun 5, 2024 to May 15, 2026⁴⁷
• Avidity Partners Management LPSCHEDULE 13G/A, 6 filings May 13, 2024 to May 12, 2026⁴⁸
• Soleus Capital Master Fund, L.P.SCHEDULE 13G/A, 2 filings Feb 3, 2026 to May 8, 2026⁴⁹
• Deep Track Capital, LPSCHEDULE 13G/A, 2 filings May 10, 2024 to May 15, 2025⁵⁰
• Franklin Templeton InvestmentsSCHEDULE 13G/A, 2 filings Jan 27, 2025 to May 9, 2025⁵¹
• Opaleye Management Inc.SCHEDULE 13G/A, 2 filings Jan 5, 2024 to Feb 14, 2025⁵²
• Martin A. LehrSCHEDULE 13G/A, 2 filings Feb 7, 2024 to Feb 12, 2025⁵³
• Hudson Bay Capital Management LPSC 13G/A, 2 filings Feb 2, 2022 to Nov 6, 2024⁵⁴
• Crossover I. Gp S.a R.l. NextechSC 13G, 1 filing May 24, 2024⁵⁵
• Affinity Asset Advisors, LLCSC 13G/A, 2 filings May 9, 2022 to Feb 13, 2024⁵⁶
• SABBY MANAGEMENT, LLCSC 13G/A, 3 filings Dec 6, 2021 to Jan 10, 2023⁵⁷
• Orin HirschmanSC 13G/A, 2 filings Oct 27, 2022 to Jan 9, 2023⁵⁸

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

1. May 6, 2024Raised $100 million in a private offering of equity²⁶ Form D: $100 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 78. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How Context Therapeutics Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARContext Therapeutics Inc.¹
• CIK0001842952
• Employer ID (EIN)86-3738787⁴
• Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company⁴
• Incorporated inDelaware⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business address2001 Market Street, Suite 3915 Unit #15, Philadelphia, PA 19103¹
• Phone267-225-7416¹
• Shares outstanding91,879,177 as of Aug 3, 2026¹¹
• Public float$57.9M as of Jun 30, 2025⁴
• AuditorCohnReznick LLP, Parsippany, New Jersey PCAOB ID 596⁴
• On EDGAR sinceMar 19, 2021¹
• Filings307 in all: 4 (69), 8-K (53), SCHEDULE 13G/A (21), 10-Q (15), 3 (15), CORRESP (15), 424B3 (11), SC 13G (11)¹
  All 34 form types

  UPLOAD (9), SC 13G/A (8), EFFECT (7), FWP (7), S-1/A (7), DEF 14A (6), DEFA14A (6), S-8 (6), 10-K (5), SCHEDULE 13G (5), PRE 14A (4), ARS (3), S-3 (3), 3/A (2), 4/A (2), 424B4 (2), 424B5 (2), DRSLTR (2), POS AM (2), S-1 (2), SEC STAFF LETTER (2), 8-A12B (1), CERT (1), D (1), DRS (1), DRS/A (1)

• Latest filingsAnnual report (10-K) Mar 23, 2026
  Quarterly report (10-Q) Aug 5, 2026
  Proxy statement (DEF 14A) Apr 28, 2026
  Latest 8-K (8-K) Aug 5, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 23, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks Context Therapeutics Inc. names in Item 1A of its 10-K filed Mar 23, 2026: 61 risks under these headings, as written.⁴

• Risks Related to Our Business and Industry
• We have never been profitable and may never achieve or maintain profitability.
• We will need to raise additional funding, which may not be available on acceptable terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product development efforts or other operations.
• If we are unable to raise substantial additional capital on acceptable terms, or at all, we may be forced to delay, reduce or eliminate some or all of our research programs, product development activities and commercialization efforts.
• If we are not able to successfully integrate recent and future acquisitions, our management’s attention could be diverted, and efforts to integrate future acquisitions could consume significant resources.
• We have a limited operating history, which makes it difficult to evaluate our current business and future prospects and may increase the risk of your investment.
• We may expend our limited resources pursuing particular research programs or product candidates that may be less successful or profitable than other programs or product candidates.
• Fluctuating foreign exchange rates could increase our operating expenses and adversely affect our results of operations.
• Inflation, geopolitical developments, global supply chain disruptions and public health concerns could adversely affect our business and results of operations.
• Changes in U.S. trade policy, including the imposition of tariffs and the resulting consequences, may have a material adverse impact on our business, financial condition, and results of operations.
• Our governing documents designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of state law actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.
• Risks Related to our Product Candidates

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Except as disclosed below, we are not presently a party to any material legal proceedings.

On February 4, 2026, the Vladimir Gusinsky Revocable Trust filed a stockholder class action complaint (the “Action”) against us and our directors in the Court of Chancery of the State of Delaware (the “Court”) asserting that (i) Article V, Section 2 of our Amended and Restated Certificate of Incorporation, as amended (the “Certificate of Incorporation”), provides for a full term of three years for directors in violation of Section 211(b) of the General Corporation Law of the State of Delaware (the “DGCL”) and (ii) Article VI, Section 1 of the Certificate of Incorporation limits removal of directors only for cause in violation of Section 141(k) of the DGCL.

On February 24, 2026, a stipulation and proposed consent judgment (the “Stipulated Judgment”) was filed with the Court regarding the Action, and on March 11, 2026, the Court approved the Stipulated Judgment, pursuant to which Article V, Section 2 and Article VI, Section 1 of the Certificate of Incorporation were determined to be invalid and unenforceable. On March 11, 2026, we filed a Certificate of Correction with the Delaware Secretary of State reflecting such provisions as invalid, unenforceable and no longer part of the Certificate of Incorporation. Accordingly, the term of office of our current members of the Board of Directors will expire at our 2026 annual meeting of stockholders, with each serving until his or her successor is duly elected and qualified or until his or her earlier death, resignation or removal. In addition, directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors.

The opening of Item 3, Legal Proceedings.⁴